Response to interferon-alpha in chronic hepatitis B with and without precore mutant strain detected by mutation site-specific assay

J Clin Gastroenterol. 2004 May-Jun;38(5):460-4. doi: 10.1097/00004836-200405000-00013.

Abstract

Goals: We investigated whether the presence of precore mutant (stop codon mutation at codon 28) affects the response to interferon-alpha in patients with chronic hepatitis B.

Background: Mutations of hepatitis B virus (HBV) may influence the response to treatment. The association of precore mutant with the response to interferon is controversial.

Study: Thirty-one Japanese patients with hepatitis B e antigen-positive chronic hepatitis were treated with natural interferon-alpha. HBV DNA with the precore mutation was assayed in serum using a mutation site-specific assay before and after treatment.

Results: Before treatment, precore mutant was detected in 22 cases (group A) and not detected in 9 cases (group B). Serum HBV DNA level before treatment was not different between the 2 groups. At the end of treatment, serum HBV DNA was decreased to undetectable levels in 13% (4 of 31). Six months after treatment, the percentage of cases with loss of hepatitis B e antigen and a decrease in the transaminase level to within the normal range was significantly higher in group B than in group A (67%, 18%, P = 0.015).

Conclusions: Chronic hepatitis without precore mutant strain before treatment is more responsive to IFN-alpha.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • DNA Mutational Analysis
  • Female
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / genetics*
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / virology
  • Humans
  • Interferon-alpha / therapeutic use*
  • Japan
  • Male
  • Mutation
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon-alpha